Amivantamab is approved for the treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, whose disease progressed on or after platinum-based chemotherapy (14, 16–18). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.